Condition: Asthma · Sponsor: Novartis Pharmaceuticals
The purpose of this study is to provide safety and tolerability, pharmacokinetics and immunogenicity data for multiple CSJ117 doses inhaled once daily compared with placebo, in adult asthma participants treated with medium or high dose ICS plus LABA alone or with additional asthma controllers (additional controllers allowed: LTRA, LAMA, Theophylline and its derivatives), who have completed the prior phase llb study CCSJ117A12201C (NCT04410523).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Bakersfield, California, United States | — |
| Novartis Investigative Site | Huntington Beach, California, United States | — |
| Novartis Investigative Site | Los Angeles, California, United States | — |
| Novartis Investigative Site | Los Angeles, California, United States | — |
| Novartis Investigative Site | Marietta, Georgia, United States | — |
| Novartis Investigative Site | White Marsh, Maryland, United States | — |
| Novartis Investigative Site | Oklahoma City, Oklahoma, United States | — |
| Novartis Investigative Site | Greenville, South Carolina, United States | — |
| Novartis Investigative Site | Boerne, Texas, United States | — |
| Novartis Investigative Site | McKinney, Texas, United States | — |
| Novartis Investigative Site | CABA, Buenos Aires, Argentina | — |
| Novartis Investigative Site | Ranelagh, Partido de Berazate, Buenos Aires, Argentina | — |
+ 46 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04946318